Filing Details
- Accession Number:
- 0001209191-22-001328
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-01-04 21:33:55
- Reporting Period:
- 2022-01-03
- Accepted Time:
- 2022-01-04 21:33:55
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 879407 | Arrowhead Pharmaceuticals Inc. | ARWR | Pharmaceutical Preparations (2834) | 460408024 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1242615 | Y Adeoye Olukotun | 177 E Colorado Blvd Ste 700 Pasadena CA 91105 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2022-01-03 | 1,890 | $64.26 | 7,110 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-01-03 | 1,916 | $65.04 | 5,194 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-01-03 | 244 | $66.25 | 4,950 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuantto a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.72 to$64.70, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of ArrowheadPharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of sharessold at each separate price within the ranges set forth in this footnote of this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.74 to$65.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of ArrowheadPharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of sharessold at each separate price within the ranges set forth in this footnote of this Form 4
Billionaire Hedge Funds
